Regeneron Pharmaceuticals（REGN）株式概要
リジェネロン・ファーマシューティカルズ・インクは、世界中の様々な疾病を治療する医薬品の発見、発明、開発、製造、商業化を行っている。 詳細
報酬
リスク分析
REGN リスクチェックを通過した。
REGN Community Fair Values
Create NarrativeSee what 164 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Regeneron Pharmaceuticals, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$634.62 |
| 52週高値 | US$821.11 |
| 52週安値 | US$476.49 |
| ベータ | 0.30 |
| 1ヶ月の変化 | -15.56% |
| 3ヶ月変化 | -19.08% |
| 1年変化 | 5.20% |
| 3年間の変化 | -12.90% |
| 5年間の変化 | 26.11% |
| IPOからの変化 | 2,904.12% |
最新ニュース
ナラティブの更新 • May 26
REGN: Fair Outlook As LAG 3 Setback Reshapes Pipeline And Product Prospects
Analysts have trimmed their fair value estimate for Regeneron Pharmaceuticals to $641 from $730, reflecting lower assumed profit margins and a reduced future P/E multiple after the recent fianlimab LAG-3 trial setbacks and related cuts to price targets across the Street. Analyst Commentary Street research has turned more cautious on Regeneron following the failed Phase 3 LAG-3 melanoma trial for fianlimab, with a series of reduced price targets and several rating downgrades.Seeking Alpha • May 18
Regeneron: Time To Forget Fianlimab (Rating Upgrade)
Summary Regeneron faced a setback after fianlimab and Libtayo failed in a phase 3 trial in first-line metastatic melanoma. These results have negative read-through to other fianlimab-based trials in melanoma. I see Regeneron as a strong buy after the pullback, as fianlimab-based combinations were not critical for long-term value creation. Return to stronger growth, expanding and maturing pipeline, and a strong balance sheet position the company well for success. Key risks include further Eylea franchise weakness and potential new clinical disappointments. Read the full article on Seeking AlphaRecent updates
ナラティブの更新 • May 26
REGN: Fair Outlook As LAG 3 Setback Reshapes Pipeline And Product Prospects
Analysts have trimmed their fair value estimate for Regeneron Pharmaceuticals to $641 from $730, reflecting lower assumed profit margins and a reduced future P/E multiple after the recent fianlimab LAG-3 trial setbacks and related cuts to price targets across the Street. Analyst Commentary Street research has turned more cautious on Regeneron following the failed Phase 3 LAG-3 melanoma trial for fianlimab, with a series of reduced price targets and several rating downgrades.Seeking Alpha • May 18
Regeneron: Time To Forget Fianlimab (Rating Upgrade)
Summary Regeneron faced a setback after fianlimab and Libtayo failed in a phase 3 trial in first-line metastatic melanoma. These results have negative read-through to other fianlimab-based trials in melanoma. I see Regeneron as a strong buy after the pullback, as fianlimab-based combinations were not critical for long-term value creation. Return to stronger growth, expanding and maturing pipeline, and a strong balance sheet position the company well for success. Key risks include further Eylea franchise weakness and potential new clinical disappointments. Read the full article on Seeking Alpha
ナラティブの更新 • May 03
REGN: Expanding Immunology And Gene Therapy Will Support Future Upside
Regeneron's analyst price target has been adjusted slightly higher to $875.31 from $873.78, as analysts factor in updated assumptions around revenue growth, profitability, and future P/E multiples following a mix of recent target hikes and trims across the Street. Analyst Commentary Recent Street research on Regeneron Pharmaceuticals shows a mix of optimism and caution, reflected in a series of price target raises and trims clustered over the past few months.ナラティブの更新 • Apr 19
REGN: Fair Outlook As Mixed Pipeline And Product Trends Shape Prospects
Regeneron Pharmaceuticals' updated analyst price target holds at $730, as analysts balance modest tweaks to growth, margins, and discount rate assumptions with recent Street research that broadly reiterates support for Dupixent, the broader pipeline, and capital return from the Sanofi repayment. Analyst Commentary Recent Street research around Regeneron points to a mixed but generally supportive tone, with several firms adjusting price targets and reiterating constructive views on Dupixent, the pipeline, and cash inflows from the Sanofi repayment.
ナラティブの更新 • Apr 04
REGN: Future Share Re Rating Seen Building On Underappreciated Immunology Pipeline
Analysts have modestly lifted their fair value estimate for Regeneron Pharmaceuticals to $1,030.49. The new estimate is supported by updated models that incorporate Street research pointing to stronger Dupixent contribution, an undervalued pipeline, and slightly higher assumed revenue growth, profit margins, and future P/E levels.ナラティブの更新 • Mar 21
REGN: Expanding Immunology Franchise Will Support Future Upside Despite Concentration Risks
Analysts have raised their price targets on Regeneron, with the modelled fair value estimate moving from about $821.12 to $873.78 as they factor in stronger contributions from Dupixent, a higher revenue growth outlook, firmer profit margins, and a slightly lower assumed future P/E multiple. Analyst Commentary Bullish and cautious voices around Regeneron are both active, with recent research focused on how much of Dupixent's profit stream and the broader pipeline are already reflected in the share price.ナラティブの更新 • Mar 07
REGN: Fair Outlook As Pipeline Optionality Offsets Product And Competition Risks
Analysts have nudged their average price target for Regeneron higher into the low $900s, reflecting views that Dupixent profitability, indication expansion, and an undervalued pipeline, including Lynozyfic, are not fully reflected in the current share price. Analyst Commentary Recent research on Regeneron centers on whether the market is giving full credit to Dupixent and the broader pipeline versus risks tied to older products and future competition.
新しいナラティブ • Mar 03
Regeneron Pharmaceuticals Inc. (REGN): The Biotech Stalwart – Defensive Growth Amid Biosimilar Headwinds in 2026.
Regeneron (REGN) is currently positioned as a defensive titan in the biotechnology sector, trading at $790.76 as of the March 2, 2026, close. While the broader healthcare index has faced pressure from regulatory pricing debates, Regeneron has demonstrated relative strength, maintaining a 1.2% year-to-date gain following a robust Q4 2025 earnings beat in late January.ナラティブの更新 • Feb 21
REGN: Fair Outlook As Future Pipeline And Spending Risks Remain
Analysts have raised their fair value estimate for Regeneron to $730 from $627, reflecting updated models that incorporate higher projected revenue growth, slightly stronger profit margins, and a modestly richer future P/E multiple, in line with a series of recent price target increases across the Street. Analyst Commentary Recent Street research on Regeneron has tilted positive, with a series of higher price targets from firms including Goldman Sachs, Citi, JPMorgan and others.ナラティブの更新 • Feb 06
REGN: 2026 Oncology Milestones Are Expected To Drive Share Re Rating
Analysts have nudged our Regeneron Pharmaceuticals fair value estimate higher to US$1,009.20 from US$995.67, reflecting updated price targets that lean on stronger modeled revenue growth assumptions, a modestly adjusted discount rate, slightly lower profit margin expectations, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Regeneron has leaned firmly positive, with a cluster of bullish analysts lifting price targets across a tight time window.ナラティブの更新 • Jan 23
REGN: Pipeline Catalysts In 2026 Are Expected To Drive Re Rating
Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals from US$890.00 to about US$995.67, reflecting higher modeled revenue growth and profit margins, alongside a slightly lower future P/E assumption and an updated discount rate. Analyst Commentary Recent research on Regeneron Pharmaceuticals has tilted clearly positive, with a series of higher price targets and supportive coverage pointing to confidence in the company’s execution, portfolio strength, and pipeline potential.ナラティブの更新 • Jan 09
REGN: Core Franchises And Pipeline Will Support Balanced Upside And Concentration Risks
Analysts have raised their fair value estimate for Regeneron Pharmaceuticals from about $781 to roughly $821. This reflects updated price targets that reference a slightly lower discount rate, modestly adjusted revenue growth assumptions, a small uptick in expected profit margins, and a higher future P/E multiple supported by recent bullish research calls from several major firms.ナラティブの更新 • Dec 25
REGN: Future Pipeline And Spending Risks Likely To Pressure Shares
Analysts have lifted their fair value estimate for Regeneron Pharmaceuticals to $627 from $543, citing faster expected revenue growth, improved long term profit margins, and a still compelling valuation multiple despite a modestly higher discount rate. Analyst Commentary Recent Street research on Regeneron highlights a generally positive stance on the company, with most firms reiterating or initiating Buy or Outperform ratings and lifting price targets following a strong third quarter.ナラティブの更新 • Dec 11
REGN: Core Franchises And Pipeline Will Support Measured Upside Amid Ongoing Risks
Regeneron Pharmaceuticals fair value estimate has been nudged higher to approximately $781 per share from about $768, as analysts factor in stronger medium term revenue growth, expanding profit margins, and a durable innovation led pipeline that supports higher long term earnings power despite modestly lower future multiple assumptions. Analyst Commentary Recent Street research on Regeneron reflects a generally constructive stance, with most firms reiterating or initiating positive ratings while modestly recalibrating price targets around execution risks and spending needs.ナラティブの更新 • Nov 27
REGN: Core Franchises And Upcoming Catalysts Will Drive Measured Upside Amid Risks
Regeneron Pharmaceuticals' analyst price target has been increased from approximately $753 to $768, as analysts highlight the company's resilient commercial base, innovative pipeline, and anticipated near-term contributions from core franchises and upcoming catalysts. Analyst Commentary Recent coverage of Regeneron Pharmaceuticals by Wall Street analysts reflects a broad consensus of confidence in the company's long-term growth drivers, while also acknowledging areas of risk that could impact future valuation and execution.分析記事 • Nov 19
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
The Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) share price has done very well over the last month, posting an...ナラティブの更新 • Nov 12
REGN: Positive Trial Results And Approval Will Drive Continued Momentum
Regeneron's analyst price target has increased from approximately $735.72 to $753.17, as analysts cite better-than-expected quarterly results and continued strength across key product lines as drivers for the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts highlight the robust Q3 results, which surpassed expectations for both revenue and earnings.分析記事 • Nov 09
Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think
Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) stock showed strength, with investors undeterred by its weak earnings...ナラティブの更新 • Oct 28
Pipeline Strength And Recent Developments Will Drive Premium Potential Ahead
Regeneron's analyst price target increased from $722.20 to $735.72, reflecting improved earnings results and confidence in the company's drug pipeline, according to recent analyst commentary. Analyst Commentary Following Regeneron Pharmaceuticals' recent earnings results and updates across its drug pipeline, analysts have issued a series of updated price targets and recommendations.ナラティブの更新 • Sep 18
Broad Pipeline And Global Access Will Build Future Success
Regeneron Pharmaceuticals’ price target was raised to $722.20 as analysts cited continued outperformance and growth potential for Dupixent and Eylea, strong late-stage trial results in myasthenia gravis, and reinforced market leadership following competitor setbacks. Analyst Commentary Bullish analysts highlighted ongoing strength and growth potential for Dupixent and Eylea, with market share remaining dominant and robust prospects for Eylea HD.株主還元
| REGN | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 0.7% | 2.9% | 2.5% |
| 1Y | 5.2% | 33.0% | 26.4% |
業界別リターン: REGN過去 1 年間で33 % の収益を上げたUS Biotechs業界を下回りました。
リターン対市場: REGNは、過去 1 年間で26.4 % のリターンを上げたUS市場を下回りました。
価格変動
| REGN volatility | |
|---|---|
| REGN Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: REGN 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: REGNの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1988 | 15,343 | Leonard Schleifer | www.regeneron.com |
リジェネロン・ファーマシューティカルズ・インク（Regeneron Pharmaceuticals, Inc.同社は眼疾患、アレルギー性疾患、炎症性疾患、心血管疾患、代謝性疾患、神経疾患、感染症、希少疾患、がん、血液疾患の治療薬候補を開発している。また、湿性加齢黄斑変性と糖尿病黄斑浮腫の治療薬EYLEA注射剤、近視性脈絡膜新生血管、糖尿病網膜症、新生血管緑内障、未熟児網膜症、アトピー性皮膚炎と喘息の治療薬デュピクセント注射剤を提供している；転移性・局所進行性皮膚扁平上皮癌治療薬Libtayo注射液、ヘテロ接合性家族性高コレステロール血症（HoFH）治療薬Praluent注射液、関節リウマチ治療薬Kevzara溶液。また、EYLEA 8mgおよびEYLEAの開発・商業化に関するBayer社とのライセンスおよび提携契約、眼および中枢神経系に発現する疾患標的を治療するRNAi治療薬の発見・開発・商業化に関するAlnylam Pharmaceuticals社、CRISPR/CasPRを推進するIntellia Therapeutics, Inc.は、CRISPR/Cas9遺伝子編集技術を活用したin vivoでの神経・筋疾患治療薬の開発、Hansoh Pharmaceuticals Group Company Limitedは、デュアルGLP-1/GIPレセプターであるHS-20094の開発・販売権の取得、Tessera Therapeutics, Inc.は、α-1抗トリプシン欠損症に対する治験用遺伝子編集療法であるTSRA-196の開発・販売を行っている。さらに、テリックス・ファーマシューティカルズ・リミテッドと戦略的提携を結び、放射性医薬品療法の開発・商業化を進めている。同社は1988年に設立され、ニューヨーク州タリータウンを拠点としている。
Regeneron Pharmaceuticals, Inc. 基礎のまとめ
| REGN 基礎統計学 | |
|---|---|
| 時価総額 | US$65.00b |
| 収益（TTM） | US$4.42b |
| 売上高(TTM) | US$14.92b |
14.6x
PER（株価収益率4.3x
P/SレシオREGN は割高か？
公正価値と評価分析を参照収益と収入
| REGN 損益計算書（TTM） | |
|---|---|
| 収益 | US$14.92b |
| 売上原価 | US$8.37b |
| 売上総利益 | US$6.55b |
| その他の費用 | US$2.12b |
| 収益 | US$4.42b |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 43.48 |
| グロス・マージン | 43.89% |
| 純利益率 | 29.65% |
| 有利子負債／自己資本比率 | 6.3% |
REGN の長期的なパフォーマンスは？
過去の実績と比較を見る| Regeneron Pharmaceuticals 配当日 | |
|---|---|
| 配当落ち日 | May 20 2026 |
| 配当支払日 | Jun 04 2026 |
| 配当落ちまでの日数 | 7 days |
| 配当支払日までの日数 | 8 days |
REGN 配当は確実ですか？
REGN 配当履歴とベンチマークを見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/26 10:54 |
| 終値 | 2026/05/26 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Regeneron Pharmaceuticals, Inc. 27 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。53
| アナリスト | 機関 |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| James Birchenough | Barclays |